Precision Oncology Programs Adapting to Ensure Patient Safety, Care During Public Health Crisis

Mar 24, 2020

|

NEW YORK – As more confirmed cases of COVID-19 are reported around the country, cancer centers and health systems specializing in precision oncology are having to adapt quickly to protect vulnerable patients from infection, while still ensuring they're getting molecularly guided treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Precision Oncology Programs Adapting to Ensure Patient Safety, Care During Public Health Crisis

To read the full story....

Breaking News

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Featured White Papers

What's Popular?

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

Full BRCA1 Gene Deletion Suspected to Contribute to Patient's Long PARP Inhibitor Response

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Sponsorships